Skip to content

AspyreRx ma.1.0.0

by Better Therapeutics

AspyreRx ma.1.0.0 is a mental health/function therapeutic software (FDA Class II; FDA product code QXC, Diabetes Digital Therapeutic Device) made by Better Therapeutics, granted FDA De Novo DEN220058 on 7 Jul 2023 and listed in FDA GUDID since 16 Oct 2023 (UDI-DI 00860011146704), active as of 22 Oct 2026.

Active United States. Also listed in GUDID (US).

De Novo

Valid until

No expiry

De Novo grant is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

De Novo DEN220058

FDA submission, from GUDID

Trust

Unverified

Source GUDID, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing Number00860011146704 UDI-DI Date16 Oct 2023ListedStatusListed GUDID: in commercial distribution
United StatesFDA De NovoDENG from GUDID De Novo granted · Direct NumberDEN220058 Date7 Jul 2023DecidedStatusActive

Official records

From the FDA record

Device description
BT-001 (AspyreRx) is a prescription-only digital therapeutic device intended to provide cognitive behavioral therapy to treat patients 18 years or older with type 2 diabetes.
MRI safety
Labeling does not contain MRI Safety Information
Natural rubber latex
No latex statement on the label
Sterility
Supplied non-sterile

From the GUDID record (AccessGUDID), as read on 22 Oct 2026, as the labeller entered it.

Across registries

2 registries list this device

  • FDA De Novo DEN220058 decided 7 Jul 2023 Active
  • FDA GUDID UDI-DI 00860011146704 listed 16 Oct 2023 Listed

Timeline

2 dated events

  1. Granted FDA De Novo DEN220058
  2. Listed FDA GUDID 00860011146704

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA De Novo Active

Specification

GUDID

Trade name
AspyreRx
Generic name
Mental health/function therapeutic software, screen-viewed
Model / reference
ma.1.0.0
Primary DI / UDI-DI
00860011146704
De Novo Number
FDA product code
QXC
GMDN term
Mental health/function therapeutic software, screen-viewed
Device class
Class II
Regulation number
880.5735
GUDID distribution status
In Commercial Distribution

Other devices from Better Therapeutics

Properties

  • Prescription use
  • Lot / batch number
Other properties (13, all answered No)